It was reported via a research article that 128 patients with atherosclerotic disease were treated with a supera stent in the femoral popliteal region.The aim of the study was to evaluate the durability and long-term patency of the supera stent to treat severe femoral popliteal lesions.All lesions were pre-dilated.Some of the lesions were pre-dilated using smaller diameter balloons than the required 1:1 vessel preparation, due to smaller diameter, (sub)occlusive lesions.Post-dilatation was done in all stents.As primary endpoints patency rates and freedom from target lesion revascularization (tlr) were calculated after 12 and 24 months.No significant patency differences were observed based on calcification rate.Post-procedure follow-ups reported the following adverse patient effects potentially related to the supera stents: death (within 66 months), occlusion, ischemia, claudication, thrombectomy (thrombus), bypass surgery, minor and major amputation.The article conclusion was that endovascular treatment of femoropopliteal disease with supera stent is safe, even in highly calcified lesions.Patency rates and freedom from target lesion revascularization (tlr) are acceptable in a real-life population.Additional details can be found in the attached article, "self-expanding interwoven nitinol stent in severe femoropopliteal arterial disease.Real life results of the supera peripheral stent system".
|
B2: date of death is estimate.B3: date of event is estimate.D4.Unique device identifier (udi#): in the absence of a reported part number, the udi cannot be calculated.D6a - implant date is estimate.The device was not returned for evaluation.A review of the lot history record could not be conducted because the part and lot number was not provided.The reported patient effect of death is listed in the supera peripheral stent system instructions for use as a potential adverse effect of peripheral percutaneous intervention.A conclusive cause for the reported death and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling.The additional adverse patient effects referenced in b5 are captured under a separate medwatch report.Attachment: article titled, "self-expanding interwoven nitinol stent in severe femoropopliteal arterial disease.Real life results of the supera peripheral stent system".
|